Provided by Tiger Trade Technology Pte. Ltd.

Clinuvel Pharmaceuticals Ltd.

8.45
0.0000
Volume:500.00
Turnover:4.00K
Market Cap:422.05M
PE:17.75
High:8.45
Open:8.45
Low:8.45
Close:8.45
52wk High:8.60
52wk Low:6.81
Shares:49.95M
Float Shares:41.26M
Volume Ratio:0.70
T/O Rate:0.00%
Dividend:0.03
Dividend Rate:0.39%
EPS(TTM):0.4762
EPS(LYR):0.4771
ROE:16.30%
ROA:11.37%
PB:2.46
PE(LYR):17.71

Loading ...

Company Profile

Company Name:
Clinuvel Pharmaceuticals Ltd.
Exchange:
PINK LIMITED
Establishment Date:
1999
Employees:
16
Office Location:
535 Bourke Street,Level 22,Melbourne,Victoria,Australia
Zip Code:
3000
Fax:
61 3 9660 4909
Introduction:
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), which provoke prolonged cellular activity; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. The company was founded in 1987 and is headquartered in Melbourne, Australia.